Huahui Ren

Huahui Ren

Auto-generated profile, based on publicly available information

Huahui Ren

BGI Genomics, Shenzhen, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZSZhun Shi
Zhun Shi
HRHuahui Ren
Huahui Ren
CLCong Lin
Cong Lin
FLFuqiang Li
Fuqiang Li
MWMeizhen Wu
Meizhen Wu
HZHuanzi Zhong
Huanzi Zhong
To deepen the understanding of tissue-resident microbiota in colorectal cancer (CRC), we analyzed whole-genome and transcriptome data from 937 patients. We identified 249 genera and 361 species commonly present in both tumors and adjacent normal tissues (NATs). Distinct microbial signatures were associated with anatomical location, tumor stages, hypermutation status, mutations in CRC driver and DNA damage repair genes, as well as consensus molecular subtypes (CMSs). Notably, the presence of the pks island and elevated abundance of Enterobacteriaceae were linked to poor prognosis specifically in CMS2 tumors. Finally, microbial risk scores derived from taxa present in tumor or NATs predicted patient prognosis independently of established clinico-molecular factors. Prognostic taxa were strongly associated with tumor transcriptomic pathways related to hypoxia, immune response, and metabolic status. These findings revealed the heterogeneity of tissue-resident microbiota and their critical role in CRC progression, highlighting potential avenues for targeted intervention.

13 March 2024 in iMeta
Verified
Journal Article
Open access
HRHuahui Ren
Huahui Ren
ZSZhun Shi
Zhun Shi
FYFangming Yang
Fangming Yang
SWShujie Wang
Shujie Wang
FYFengyi Yuan
Fengyi Yuan
HZHuanzi Zhong
Huanzi Zhong
The administration of oral antidiabetic drugs (OADs) to patients with type 2 diabetes elicits distinct and shared changes in the gut microbiota, with acarbose and berberine exhibiting greater impacts on the gut microbiota than metformin, vildagliptin, and glipizide. The baseline gut microbiota strongly associates with treatment responses of OADs.